# Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?

> **NCT03038321** · PHASE4 · UNKNOWN · sponsor: **Mansoura University** · enrollment: 150 (actual)

## Conditions studied

- Non-Muscle-invasive Bladder Cancer (NMIBC)
- Bacillus Calmette-Guerin (BCG) Cystitis
- Intra-vesical Instillation

## Interventions

- **DRUG:** sofenacin
- **DRUG:** Tavanic
- **DRUG:** Xefo

## Key facts

- **NCT ID:** NCT03038321
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-01
- **Primary completion:** 2017-12
- **Final completion:** 2019-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03038321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03038321, "Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03038321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*